rebel Financial rebel Financial
← All Posts
VIR

Viridian Therapeutics, Inc.

June 03, 2026 • Author: Phil Ratcliff
Item Proposal Vote
1 To elect the two Class II director nominees named in the Proxy Statement to serve until the 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified ✓ For
2 To ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 ✓ For
3 To approve, on an advisory basis, the compensation of the Company’s named executive officers ✓ For
4 To approve, on an advisory basis, the frequency of holding an advisory vote on the compensation of the Company’s named executive officers 1 Year
Attachments
📄
VRDN_ANNUAL_REPORT_2025.pdf 4.7 MB
📄
VRDN_PROXY_STATEMENT.pdf 1.6 MB
This article was written for information purposes only and its content should not be construed by any consumer and/or prospective client as rebel Financial's solicitation to affect, or attempt to affect transactions in securities, or the rendering of personalized investment advice for compensation. No client or prospective client should assume that any such discussion serves as the receipt of, or a substitute for, personalized advice from rebel Financial, or from any other investment professional. See our disclosures page for more information.